HHS Proposes FDA Enforcement Discretion for Unproven Peptide Drugs

The US Department of Health and Human Services has filed an "Interim Access Policy" on peptide drugs with the White House Office of Management and Budget, according to Ars Technica, citing people familiar with the proposal. The mechanism under review would grant the Food and Drug Administration "enforcement discretion" over a class of injectable peptides currently restricted from compounding pharmacies, allowing the agency to decline action against producers its own staff scientists determined lack sufficient safety and efficacy data. For readers who track the evidentiary foundations of public health mandates, the filing represents a procedural workaround that substitutes administrative discretion for the standard rulemaking pathway.

The Mechanism and Its Evidentiary Threshold

Enforcement discretion, as applied here, permits the FDA to refrain from exercising regulatory authority it technically retains. The interim policy would function as a de facto market-access route while a formal rulemaking, which the Associated Press notes could extend across multiple rounds of public comment, proceeds in parallel. The underlying scientific record is not altered by the policy's adoption; the record remains what FDA career staff documented in 2023, when twelve peptides were removed from the compounding-eligible list after review concluded they lacked data on safety and efficacy and, in some cases, presented documented harms.

Removing a restriction absent new data does not constitute a finding. It constitutes a choice to defer enforcement pending a process whose evidentiary requirements are not specified in the public OMB filing notice. HHS did not respond to a request for comment from Ars Technica.

Panel Composition and the Override of Staff Findings

Of nine members Health Secretary Robert F. Kennedy Jr. appointed in June to the 13-member advisory panel reviewing the peptides, at least six maintain documented ties to peptide-related businesses or clinics. In a July meeting, the panel voted to recommend restoring six of the first seven peptides to the compounding list, overruling the career scientists whose 2023 analysis had prompted their removal.

The Center for Science in the Public Interest has formally objected. Pete Lurie, CSPI president and a former FDA associate commissioner, stated: "If this conflicted committee's recommendations stand, charlatans will continue to put unsuspecting consumers at risk of serious injury by making unsupported claims about their [peptides'] purported benefits." CSPI's letter to Acting FDA Commissioner Kyle Diamantas urges disregard of the panel's recommendations on conflict-of-interest grounds.

What Remains Unverified

The OMB posting does not contain policy text. Whether the FDA will formally adopt the panel's recommendation through rulemaking remains pending. The interim access policy itself, if cleared, does not constitute a safety determination; it constitutes an administrative decision to suspend enforcement against entities whose products the agency's own reviewers found insufficiently characterized.

For observers who watch political appointees override career scientific staff on questions of population-level exposure, the sequence is structurally familiar: a restrictive staff finding, an industry-aligned panel vote, and a procedural mechanism designed to bypass the evidentiary standard rather than meet it. What to monitor next is whether the OMB clearance converts the proposal into operative agency guidance, and whether any accompanying documentation discloses the specific compounds, indications, and exposure populations the discretion would cover.